Search results for "Isotope Labeling"

showing 10 items of 54 documents

Whole-body pharmacokinetics of HDAC inhibitor drugs, butyric acid, valproic acid and 4-phenylbutyric acid measured with carbon-11 labeled analogs by …

2013

The fatty acids, n-butyric acid (BA), 4-phenylbutyric acid (PBA) and valproic acid (VPA, 2-propylpentanoic acid) have been used for many years in the treatment of a variety of CNS and peripheral organ diseases including cancer. New information that these drugs alter epigenetic processes through their inhibition of histone deacetylases (HDACs) has renewed interest in their biodistribution and pharmacokinetics and the relationship of these properties to their therapeutic and side effect profiles. In order to determine the pharmacokinetics and biodistribution of these drugs in primates, we synthesized their carbon-11 labeled analogues and performed dynamic positron emission tomography (PET) in…

Cancer ResearchBiodistributionSide effectPharmacologyPhenylbutyrateArticleButyric acidchemistry.chemical_compoundPharmacokineticsmedicineAnimalsRadiology Nuclear Medicine and imagingTissue DistributionCarbon RadioisotopesValproic AcidRadiochemistryValproic AcidBrainLipid metabolismBlood ProteinsBlood proteinsPhenylbutyratesHistone Deacetylase InhibitorschemistryIsotope LabelingPositron-Emission TomographyMolecular MedicineButyric AcidFemalemedicine.drugPapio
researchProduct

Morphological transformation and DNA adduct formation by dibenz[a,h]anthracene and its metabolites in C3H10T1/2CL8 cells.

1994

The major routes of metabolic activation of dibenz[a,h]-anthracene (DBA) have been studied in transformable C3H10T1/2CL8 (C3H10T1/2) mouse embryo fibroblasts in culture. The morphological transforming activities of three potential intermediates formed by metabolism of DBA by C3H10T1/2 cells, trans-3,4-dihydroxy-3,4-dihydro-DBA-(DBA-3,4-diol), trans-dihydroxy-3,4-dihydro-DBA-anti-1,2-oxide (DBA-3,4-diol-1,2-oxide) and DBA-5,6-oxide were determined. DBA-3,4-diol-1,2-oxide was a strong morphological transforming agent giving a mean of 73% dishes with Type II or III foci and 1.63 Type II and III foci per dish at 0.5 microgram/ml. DBA-3,4-diol produced a mean of 42% dishes with Type II or III fo…

Cancer ResearchBiologychemistry.chemical_compoundDNA AdductsMiceStructure-Activity Relationshippolycyclic compoundsmedicineBenz(a)AnthracenesDeoxyguanosineDibenz(ah)anthraceneAnimalsFibroblastCarcinogenBiotransformationMice Inbred C3HGeneral MedicineMetabolismFibroblastsIn vitromedicine.anatomical_structureCell Transformation NeoplasticchemistryBiochemistryCell cultureIsotope LabelingOxidation-ReductionPhosphorus RadioisotopesDNACarcinogenesis
researchProduct

Validation of (68)Ge/(68)Ga generator processing by chemical purification for routine clinical application of (68)Ga-DOTATOC.

2008

Abstract Introduction Imaging of somatostatin receptor expressing tumours has been greatly enhanced by the use of 68 Ga-DOTATOC and PET/CT. Methods In this work, a purification method for the 68 Ge/ 68 Ga generator eluate and a method to produce 68 Ga-DOTATOC suitable for clinical use were evaluated. The generator eluate was purified and concentrated on a cation-exchange cartridge in HCl/acetone media. The efficacy of this procedure in eliminating metal impurities from the 68 Ga solution was investigated by ICP-MS. The radiotracer quality was evaluated by radio-TLC, GC and γ-ray spectrometry. Results 68 Ga-DOTATOC preparations ( n =33) were carried out with a mean synthesis yield of 59.3±2.…

Cancer ResearchGenerator (computer programming)ChromatographyElutionIon chromatographyGallium RadioisotopesMass spectrometryOctreotide68ga dotatocchemistry.chemical_compoundchemistryYield (chemistry)Isotope LabelingPositron-Emission TomographyAcetoneOrganometallic CompoundsMolecular MedicineRadiology Nuclear Medicine and imagingPurification methodsClinical MedicineRadiopharmaceuticalsNuclear medicine and biology
researchProduct

Labeling and preliminary in vivo assessment of niobium-labeled radioactive species: A proof-of-concept study.

2016

Abstract The application of radionuclide-labeled biomolecules such as monoclonal antibodies or antibody fragments for imaging purposes is called immunoscintigraphy . More specifically, when the nuclides used are positron emitters, such as zirconium-89, the technique is referred to as immuno-PET . Currently, there is an urgent need for radionuclides with a half-life which correlates well with the biological kinetics of the biomolecules under question and which can be attached to the proteins by robust labeling chemistry. 90 Nb is a promising candidate for in vivo immuno-PET , due its half-life of 14.6h and low β + energy of E mean =0.35MeV per decay. 95 Nb on the other hand, is a convenient …

Cancer ResearchPathologymedicine.medical_specialtyBiodistributionmedicine.drug_classMetaboliteNiobiumDeferoxamineMonoclonal antibody030218 nuclear medicine & medical imagingImmunoscintigraphy03 medical and health scienceschemistry.chemical_compoundMice0302 clinical medicineChloridesDrug StabilityIn vivomedicineAnimalsRadiology Nuclear Medicine and imagingTissue DistributionRadioisotopesOxalatesChemistryIn vitroBevacizumab030220 oncology & carcinogenesisIsotope LabelingPositron-Emission TomographyBiophysicsMolecular MedicineSpecific activityFemaleEx vivoHalf-LifeNuclear medicine and biology
researchProduct

Desferrioxamine as an appropriate chelator for 90Nb: Comparison of its complexation properties for M-Df-Octreotide (M=Nb, Fe, Ga, Zr)

2014

The niobium-90 radioisotope ((90)Nb) holds considerable promise for use in immuno-PET, due to its decay parameters (t½ = 14.6h, positron yield=53%, Eß(+)(mean) = 0.35 MeV and Eß(+)(max) = 1.5 MeV). In particular, (90)Nb appears well suited to detect in vivo the pharmacokinetics of large targeting vectors (50-150 kDa). In order to be useful for immuno-PET chelators are required to both stabilize the radionuclide in terms of coordination chemistry and to facilitate the covalent attachment to the targeting vector. Different chelators were evaluated for this purpose in terms of radiolabelling efficiency and stability of the radiolabelled Nb(V) complex and in order to determine the most suitable…

Cancer ResearchStereochemistryNiobiumMetal ions in aqueous solutionKineticsOctreotideRadiation DosageCoordination complexTransmetalationDrug StabilityMaterials TestingMoleculeRadiology Nuclear Medicine and imagingChelationChelating AgentsIonsRadioisotopeschemistry.chemical_classificationChemistryMetalsCovalent bondIsotope LabelingMolecular MedicineRadiopharmaceuticalsNuclear chemistryConjugateNuclear Medicine and Biology
researchProduct

Synthesis and PET studies of [11C-cyano]letrozole (Femara®), an aromatase inhibitor drug

2009

Abstract Introduction Aromatase, a member of the cytochrome P 450 family, converts androgens such as androstenedione and testosterone into estrone and estradiol, respectively. Letrozole (1-[bis-(4-cyanophenyl)methyl]-1 H -1,2,4-triazole; Femara) is a high-affinity aromatase inhibitor ( K i =11.5 nM) that has Food and Drug Administration approval for breast cancer treatment. Here we report the synthesis of carbon-11-labeled letrozole and its assessment as a radiotracer for brain aromatase in the baboon. Methods Letrozole and its precursor (4-[(4-bromophenyl)-1 H -1,2,4-triazol-1-ylmethyl]benzonitrile) were prepared in a two-step synthesis from 4-cyanobenzyl bromide and 4-bromobenzyl bromide,…

Cancer Researchmedicine.medical_specialtymedicine.drug_classEstronePharmacologyArticlechemistry.chemical_compoundAromatasePharmacokineticsInternal medicineNitrilesmedicineAnimalsRadiology Nuclear Medicine and imagingAndrostenedioneCarbon RadioisotopesAromataseTestosteroneAromatase inhibitorbiologyChemistryAromatase InhibitorsLetrozoleBrainTriazolesEndocrinologyFree fractionIsotope LabelingPositron-Emission TomographyLetrozolebiology.proteinMolecular MedicineFemaleRadiopharmaceuticalsmedicine.drugPapio
researchProduct

Profiling of RNA modifications by multiplexed stable isotope labelling

2014

The combination of (15)N/(13)C stable isotope labelling (SIL) and LC-MS/MS revealed a total of 52 modifications in RNA from E. coli and yeast, including 10 previously undescribed modifications. Two modifications, N-ribosylnicotinamide and 2-methylthioadenosine, were newly detected in species hitherto thought not to contain these modifications.

ChemistryStable isotope ratioMetals and AlloysRNASaccharomyces cerevisiaeGeneral ChemistryTandem mass spectrometryCatalysisYeastSurfaces Coatings and FilmsElectronic Optical and Magnetic MaterialsBiochemistryTandem Mass SpectrometryIsotope LabelingLabellingEscherichia coliMaterials ChemistryCeramics and CompositesRNAChromatography LiquidChemical Communications
researchProduct

Processing of Generator-Produced 68Ga for Medical Application

2007

The (68)Ge/(68)Ga generator provides an excellent source of positron-emitting (68)Ga. However, newly available "ionic" (68)Ge/(68)Ga radionuclide generators are not necessarily optimized for the synthesis of (68)Ga-labeled radiopharmaceuticals. The eluates have rather large volumes, a high concentration of H(+) (pH of 1), a breakthrough of (68)Ge, increasing with time or frequency of use, and impurities such as stable Zn(II) generated by the decay of (68)Ga, Ti(IV) as a constituent of the column material, and Fe(III) as a general impurity.We have developed an efficient route for the processing of generator-derived (68)Ga eluates, including the labeling and purification of biomolecules. Prec…

ChromatographyAqueous solutionElutionIon chromatographyGallium RadioisotopesFraction (chemistry)Hydrochloric acidEquipment DesignReference StandardsEquipment Failure Analysischemistry.chemical_compoundColumn chromatographychemistryGermanyIsotope LabelingAcetoneRadiology Nuclear Medicine and imagingRadionuclide GeneratorJournal of Nuclear Medicine
researchProduct

Spectroscopic, radiochemical, and theoretical studies of the Ga3+-N-2-hydroxyethyl piperazine-N'-2-ethanesulfonic acid (HEPES buffer) system: evidenc…

2013

Recent reports have claimed a superior performance of HEPES buffer in comparison to alternative buffer systems for 67/68 Ga labeling in aqueous media. In this paper we report spectroscopic (1H and 71 Ga NMR), radiochemical, mass spectrometry and theoretical modeling studies on the Ga3+/HEPES system (HEPES = N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid) performed with the aim of elucidating a potential contribution of HEPES in the 68/67 Ga radiolabeling process. Our results demonstrate that HEPES acts as a weakly but competitive chelator of Ga3+ and that this interaction depends on the relative Ga3+: HEPES concentration. A by-product formed in the labeling mixture has been identified …

Contrast MediaGallium Radioisotopes010402 general chemistryMass spectrometry01 natural sciencesHepes bufferchemistry.chemical_compoundRadiology Nuclear Medicine and imagingChelationComputer SimulationHEPESChromatographyAqueous medium010405 organic chemistrySpectrum AnalysisMagnetic Resonance Imaging0104 chemical sciences3. Good healthPiperazinechemistryModels ChemicalDrug DesignIsotope LabelingProton NMREthanesulfonic acidRadiopharmaceuticalsHEPESNuclear chemistryContrast mediamolecular imaging
researchProduct

Hybrid Chelator-Based PSMA Radiopharmaceuticals: Translational Approach

2021

(1) Background: Prostate-specific membrane antigen (PSMA) has been extensively studied in the last decade. It became a promising biological target in the diagnosis and therapy of PSMA-expressing cancer diseases. Although there are several radiolabeled PSMA inhibitors available, the search for new compounds with improved pharmacokinetic properties and simplified synthesis is still ongoing. In this study, we developed PSMA ligands with two different hybrid chelators and a modified linker. Both compounds have displayed a promising pharmacokinetic profile. (2) Methods: DATA5m.SA.KuE and AAZTA5.SA.KuE were synthesized. DATA5m.SA.KuE was labeled with gallium-68 and radiochemical yields of various…

Diagnostic ImagingGlutamate Carboxypeptidase IIBiodistributionmedia_common.quotation_subjectPharmaceutical ScienceOrganic chemistryChemistry Techniques Syntheticurologic and male genital diseasesArticleAnalytical ChemistryTranslational Research BiomedicalMicechemistry.chemical_compoundhybrid chelatorNude mouseQD241-441In vivoNeoplasmsDrug DiscoveryLNCaPAnimalsHumansChelationradionuclide diagnosis and therapyPhysical and Theoretical ChemistryInternalizationChelating Agentsmedia_commonMolecular StructurebiologyChemistryRadiochemistrybiology.organism_classificationDisease Models AnimalKineticsChemistry (miscellaneous)Isotope LabelingAntigens SurfaceHeterograftsMolecular MedicineRadiopharmaceuticalsAmmonium acetateEx vivoprostate specific membrane antigen PSMAProtein BindingMolecules
researchProduct